摘要:
The present invention provides a needleless syringe having, accommodated therein, a pharmaceutical preparation containing genes and/or analogues thereof. A needleless syringe comprising: a medical agent chamber 22 having one or multiple nozzle bore(s) 25 and accommodated with a medical agent L, and a syringe main body 12 being provided with pressure application means 32 to apply pressure on the medical agent L toward a direction of the nozzle bore (s) 25 and effect emission of the medical agent L through the nozzle bore (s) 25, wherein the medical agent L is a pharmaceutical preparation containing genes and/or analogues thereof. Examples of the medical agent L include pharmaceutical preparation containing HGF gene and pharmaceutical preparation containing NF-κB decoy oligonucleotide.
摘要:
Medicinal compositions for angiogenic therapy which contain as the active ingredients at least one member selected from among substances having a vasodilating effect and/or a platelet aggregation inhibitory effect and substances producing the same, and a gene encoding an angiogenesis factor; agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor which contain as the active ingredient at least one member selected from among substances having a vasodilating effect and/or a platelet aggregation inhibitory effect and substances producing the same; an angiogenic agent which contains prostacyclin synthase gene as the active ingredient; medicinal compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; an agent for potentiating the angiogenic effect of a gene encoding an angiogenesis factor which contain ets-1 gene as the active ingredient; and an angiogenic agent which contains ets-1 gene as the active ingredient.
摘要:
Medicinal compositions for angiogenic therapy which contain as the active ingredients at least one member selected from among substances having a vasodilating effect and/or a platelet aggregation inhibitory effect and substances producing the same, and a gene encoding an angiogenesis factor; agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor which contain as the active ingredient at least one member selected from among substances having a vasodilating effect and/or a platelet aggregation inhibitory effect and substances producing the same; an angiogenic agent which contains prostacyclin synthase gene as the active ingredient; medicinal compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; an agent for potentiating the angiogenic effect of a gene encoding an angiogenesis factor which contain ets-1 gene as the active ingredient; and an angiogenic agent which contains ets-1 gene as the active ingredient.
摘要:
The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.